Cargando…

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-small-cell lung cancer (NSCLC) patients. Atezolizumab, an anti-PD-L1 agent, figures among the drugs that provide previously unenvisaged outcomes in the pretreated set...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137949/ https://www.ncbi.nlm.nih.gov/pubmed/30237696 http://dx.doi.org/10.2147/DDDT.S124380

Ejemplares similares

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
por: Bordi, Paola, et al.
Publicado: (2016)

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
por: Leonetti, Alessandro, et al.
Publicado: (2020)

Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
por: Guaitoli, Giorgia, et al.
Publicado: (2023)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi, Giulio, et al.
Publicado: (2017)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
por: Facchinetti, Francesco, et al.
Publicado: (2020)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
por: Bersanelli, Melissa, et al.
Publicado: (2021)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review
por: Verzè, Michela, et al.
Publicado: (2022)

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
por: Camerini, Andrea, et al.
Publicado: (2022)

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2019)

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
por: Sothornwit, Jin, et al.
Publicado: (2019)

Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2020)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report
por: Tomic, Kresimir, et al.
Publicado: (2023)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2021)

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
por: Von, Cheong E, et al.
Publicado: (2021)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
por: Coffey, David G., et al.
Publicado: (2022)

Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review
por: Arakawa, Masafumi, et al.
Publicado: (2018)

Atezolizumab-induced psoriasis in a patient with metastatic lung cancer—a case report
por: Mao, Mian, et al.
Publicado: (2020)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
por: Yamakawa, Hideaki, et al.
Publicado: (2019)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
por: Chirasuthat, Phatcharawat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3sfrmbbq201smpekh063ckrs4n